Plain-English translation of NCT06779435 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a medication called tucidinostat when combined with chemotherapy to treat diffuse large B-cell lymphoma (DLBCL), a type of aggressive blood cancer. The study is enrolling newly diagnosed patients who have never received treatment before. Researchers want to see whether adding this medication to standard chemotherapy helps patients with this disease.
DLBCL is a serious cancer that doesn't respond well to standard treatment in all patients. This medication targets changes in cancer cells and may work better when combined with chemotherapy, but doctors need to test this in real-world patient care to know if it actually helps.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy combined with tucidinostat as your first treatment for lymphoma. The study is divided into two groups based on your age and overall health: those 80 years or older (or younger with other health conditions) receive a gentler chemotherapy combination, while others receive standard-dose chemotherapy. Your doctor will monitor you during treatment visits and track how well the medication combination works for your cancer.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Sponsor
Ruijin Hospital
Enrollment target
~400 participants
Started
January 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pengpeng Xu, professor
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.